Summary
SOLME PHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €1.0m and a net result of €79,875. Equity is growing by about 13% per year across the filed financial years. Its solvency ranks better than 53% of 6,680 sector peers (NACE 64, financial year 2025). The company has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- SOLMÉ PHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Eikenlei 13B, Sint-Job-in-‘t-Goor (Brecht)” (deed in Dutch)
Who represents it, and how
- Board ruleHow the board is made up, meets and takes decisions.
- “Van benoemende vergadering tot gewone vergadering in boekjaar van verstrijken volgens benoemingsbesluit, één of meer” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Gelijk recht in winstverdeling en vereffeningsaldo, 186” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Second Tuesday of June